In patients whose tumor harbors a BRAF mutation and who are not eligible for clinical trial participation, treatment with BRAF/MEK targeted therapy should be considered, and readers are referred elsewhere for guidance on administration of these agents [68]. Here, MAP2K7 is linked to neoplasm.